4.7 Article

Free-Operant Avoidance Behavior by Rats after Reinforcer Revaluation Using Opioid Agonists and D-Amphetamine

Journal

JOURNAL OF NEUROSCIENCE
Volume 34, Issue 18, Pages 6286-6293

Publisher

SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.4146-13.2014

Keywords

avoidance; D-amphetamine; morphine; nucleus accumbens shell; periacqueductal gray; revaluation

Categories

Funding

  1. Wellcome Trust [089589/Z/09/Z, 093875/Z/10Z]
  2. Medical Research Council [G1000183]
  3. Medical Research Council Case studentship
  4. MRC [G1000183] Funding Source: UKRI
  5. Medical Research Council [G1000183, G0001354, G0001354B] Funding Source: researchfish

Ask authors/readers for more resources

The associative processes that support free-operant instrumental avoidance behavior are still unknown. We used a revaluation procedure to determine whether the performance of an avoidance response is sensitive to the current value of the aversive, negative reinforcer. Rats were trained on an unsignaled, free-operant lever press avoidance paradigm in which each response avoided or escaped shock and produced a 5 s feedback stimulus. The revaluation procedure consisted of noncontingent presentations of the shock in the absence of the lever either paired or unpaired with systemic morphine and in a different cohort with systemic D-amphetamine. Rats were then tested drug free during an extinction test. In both the D-amphetamine and morphine groups, pairing of the drug and shock decreased subsequent avoidance responding during the extinction test, suggesting that avoidance behavior was sensitive to the current incentive value of the aversive negative reinforcer. Experiment 2 used central infusions of D-Ala(2), NMe-Phe(4), Gly-ol(5)]-enkephalin (DAMGO), a mu-opioid receptor agonist, in the periacqueductal gray and nucleus accumbens shell to revalue the shock. Infusions of DAMGO in both regions replicated the effects seen with systemic morphine. These results are the first to demonstrate the impact of revaluation of an aversive reinforcer on avoidance behavior using pharmacological agents, thereby providing potential therapeutic targets for the treatment of avoidance behavior symptomatic of anxiety disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available